Kidney-specific proteins in patients receiving aprotinin at high- and low-dose regimens during coronary artery bypass graft with cardiopulmonary bypass

被引:27
作者
Faulí, A
Gomar, C
Campistol, JM
Alvarez, L
Manig, AM
Matute, P
机构
[1] Univ Barcelona, Hosp Clin, Dept Anesthesiol, E-08036 Barcelona, Spain
[2] Univ Barcelona, Hosp Clin, Dept Nephrol, E-08036 Barcelona, Spain
[3] Univ Barcelona, Hosp Clin, Dept Biochem Lab, E-08036 Barcelona, Spain
[4] Res & Dev Board, Barcelona, Spain
关键词
APROTININ; KIDNEY FUNCTION TESTS; alpha(1)-microglobulin; beta-glucosaminidase; CORONARY ARTERY BYPASS; CARDIOPULMONARY BYPASS;
D O I
10.1017/S0265021505001109
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background and objective: The aim was to determine whether the administration of aprotinin can cause deleterious effects on renal function in cardiac surgery with cardiopulmonary bypass (CPB). Methods: Sixty consecutive patients with normal preoperative renal function undergoing elective coronary artery bypass surgery with CPB using the same anaesthetic; CPB and surgical protocols were randomized into three groups. Patients received placebo (Group 1), low-dose aprotinin (Group 2) or high-dose aprotinin (Group 3). Renal parameters measured were plasma creatinine, alpha(1)-microglobulin and beta-glucosaminidase (P-NAG) excretion. Measurements were performed before surgery, during CPB and 24 and 72 h, and 7 and 40 days postoperatively. Results: In the three groups, alpha(1)-microglobulin and P-NAG excretions significantly increased during CPB, at 24 and 72h, and 7 days postoperatively (P < 0.05) and had returned to preoperative levels at postoperative day 40. Plasma creatinine levels were within normal values at times recorded. In Groups 2 and 3, alpha(1)-microglobulin excretion during CPB was significantly higher than in Group 1 (P < 0.00 1), and 24 h after surgery it still remained significantly higher in Group 3 compared to Groups 1 and 2 (P < 0.05). Conclusions: Aprotinin caused a significant increase in alpha(1)-microglobulin excretion but not in beta-NAG excretion during CPB, which may be interpreted as a greater renal tubular overload without tubular damage. This effect persisted for 24 h after surgery when high-dose aprotinin doses had been administered. Creatinine plasma levels were not sensitive to detect these prolonged renal effects in our study.
引用
收藏
页码:666 / 671
页数:6
相关论文
共 19 条
[1]   On-pump versus off-pump coronary revascularization: Evaluation of renal function [J].
Ascione, R ;
Lloyd, CT ;
Underwood, MJ ;
Gomes, WJ ;
Angelini, CD .
ANNALS OF THORACIC SURGERY, 1999, 68 (02) :493-498
[2]   APROTININ THERAPY IN CARDIAC OPERATIONS - A REPORT ON USE IN 41 CARDIAC CENTERS IN THE UNITED-KINGDOM [J].
BIDSTRUP, BP ;
HARRISON, J ;
ROYSTON, D ;
TAYLOR, KM ;
TREASURE, T .
ANNALS OF THORACIC SURGERY, 1993, 55 (04) :971-976
[3]  
BLAUHUT B, 1991, J THORAC CARDIOV SUR, V101, P958
[4]   RETRACTED: Kidney-specific proteins in elderly patients undergoing cardiac surgery with cardiopulmonary bypass (Retracted Article) [J].
Boldt, J ;
Brenner, T ;
Lang, J ;
Kumle, B ;
Isgro, F .
ANESTHESIA AND ANALGESIA, 2003, 97 (06) :1582-1589
[5]  
Dietrich W, 1992, J Cardiothorac Vasc Anesth, V6, P324, DOI 10.1016/1053-0770(92)90150-6
[6]   Pattern of renal dysfunction associated with myocardial revascularization surgery and cardiopulmonary bypass [J].
Faulí, A ;
Gomar, C ;
Campistol, JM ;
Alvarez, L ;
Manig, AM ;
Mature, P .
EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 2003, 20 (06) :443-450
[7]   EFFECTS OF HIGH-DOSE APROTININ ON RENAL-FUNCTION IN AORTOCORONARY BYPASS-GRAFTING [J].
FEINDT, PR ;
WALCHER, S ;
VOLKMER, I ;
KELLER, HE ;
STRAUB, U ;
HUWER, H ;
SEYFERT, UT ;
PETZOLD, T ;
GAMS, E .
ANNALS OF THORACIC SURGERY, 1995, 60 (04) :1076-1080
[8]  
Jung DJ, 1999, HASTINGS LAW J, V50, P861
[9]   Preoperative alpha(2)-adrenergic receptor agonists prevent the deterioration of renal function after cardiac surgery: Results of a randomized, controlled trial [J].
Kulka, PJ ;
Tryba, M ;
Zenz, M .
CRITICAL CARE MEDICINE, 1996, 24 (06) :947-952
[10]   APROTININ FOR CORONARY-BYPASS OPERATIONS - EFFICACY, SAFETY, AND INFLUENCE ON EARLY SAPHENOUS-VEIN GRAFT PATENCY - A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].
LEMMER, JH ;
STANFORD, W ;
BONNEY, SL ;
BREEN, JF ;
CHOMKA, EV ;
ELDREDGE, WJ ;
HOLT, WW ;
KARP, RB ;
LAUB, GW ;
LIPTON, MJ ;
SCHAFF, HV ;
TATOOLES, CJ ;
RUMBERGER, JA .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1994, 107 (02) :543-553